Canntab Financial Statements From 2010 to 2024
| CTABF Stock | USD 0.0001 0.00 0.00% |
Check Canntab Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Canntab Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Canntab financial statements analysis is a perfect complement when working with Canntab Therapeutics Valuation or Volatility modules.
Canntab |
Canntab Therapeutics Limited Company Current Valuation Analysis
Canntab Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Canntab Therapeutics Current Valuation | 1.73 M |
Most of Canntab Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Canntab Therapeutics Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Canntab Therapeutics Limited has a Current Valuation of 1.73 M. This is 99.99% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The current valuation for all United States stocks is 99.99% higher than that of the company.
Canntab Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Canntab Therapeutics's current stock value. Our valuation model uses many indicators to compare Canntab Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Canntab Therapeutics competition to find correlations between indicators driving Canntab Therapeutics's intrinsic value. More Info.Canntab Therapeutics Limited is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Canntab Therapeutics' earnings, one of the primary drivers of an investment's value.About Canntab Therapeutics Financial Statements
Canntab Therapeutics stakeholders use historical fundamental indicators, such as Canntab Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Canntab Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Canntab Therapeutics' assets and liabilities are reflected in the revenues and expenses on Canntab Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Canntab Therapeutics Limited. Please read more on our technical analysis and fundamental analysis pages.
Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. Canntab Therapeutics Limited is headquartered in Markham, Canada. Canntab Therapeutics is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Canntab Pink Sheet
Canntab Therapeutics financial ratios help investors to determine whether Canntab Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Canntab with respect to the benefits of owning Canntab Therapeutics security.